INTRODUCTION
Impaired DNA repair is a driving force for carcinogenesis. Base excision repair (BER) is required for the accurate removal of bases that have been damage by alkylation, oxidation or ring-saturation (Dianov and Hubscher, 2013; Kim and Wilson, 2012; Wallace et al., 2012) .
DNA polymerase β (pol β) is a key factor in BER (Nicolay et al., 2012; Wallace et al., 2012; Yamtich and Sweasy, 2010) . The pol β gene is localised to p11 region of chromosome 8, a hot spot for chromosomal breaks, losses and amplifications in breast cancer (Armes et al., 2004; Kerangueven et al., 1994; Pole et al., 2006; Sigbjornsdottir et al., 2000; Tagawa et al., 2003; Ugolini et al., 1999; Venter et al., 2005) . The pol β gene encodes a 39kDa protein with two functional domains; the N-terminal domain is essential for the dRP lyase activity and the C-terminal domain performs the nucleotidyl transferase activity during BER. Pol β interacts with several components of the BER machinery such as XRCC1, FEN1, PARP1, APE1 and ligase III to accomplish its biochemical functions (Nicolay et al., 2012; Wallace et al., 2012; Yamtich and Sweasy, 2010) .
Pol β deficiency in mice is embryonically lethal (Gu et al., 1994) and embryonic fibroblasts derived from such mice are hypersensitive to alkylating agents (Poltoratsky et al., 2005; Sobol et al., 1996) . Depletion of pol β expression by siRNA in human cancer cell lines is associated with sensitivity to chemotherapy (Albertella et al., 2005; Yang et al., 2010) . On the other hand, pol β overexpression in pre-clinical models is associated with relative resistance to DNA damaging agents (Canitrot et al., 1998; Nicolay et al., 2012) . Germ line polymorphism of pol β gene (rs3136797) that encodes a pol β variant with a low catalytic activity has been recently shown to induce cellular transformation and may be associated with increased cancer susceptibility (Yamtich et al., 2010) . About 30% of human tumours appear to express pol β variant proteins (such as K289M, I260M) which can induce cellular transformation in vitro, associated with aggressive mutator phenotype (Starcevic et al., 2004) . Moreover, pol β mRNA expression may also be dysregulated in certain tumours. In a small study of 68 human tumours of diverse origin that also included nine breast tumours, pol β mRNA was found to be low in 20% of breast cancer samples (Albertella et al., 2005) .
Our hypothesis is that in breast cancers with aberrations at chromosome 8p, alterations to pol β gene copy number and the consequent changes in pol β mRNA and/or protein levels could influence breast cancer pathogenesis and influence clinical outcomes in patients. In the current study, we have conducted a comprehensive evaluation of pol β by array comparative genomic hybridization (CGH), gene expression profiling and immunohistochemistry in large cohorts of breast cancer. We provide the first evidence that Pol β deficiency is associated with aggressive breast cancers. In ER positive breast cancers specifically, our data suggest that pol β could influence tamoxifen response and may allow therapy stratification.
Material and Methods

Tumour samples
We have investigated multiple cohorts of breast tumours for the analyses described here. We have obtained appropriate consent and the studies were approved by the relevant research ethics boards.
A. Breast cancer cohorts
Discovery cohort
Pol β gene expression was investigated in Uppsala cohort that was originally composed of 315 women representing 65% of all breast cancers resected in Uppsala County, Sweden, from January 1, 1987 , to December 31, 1989 . Demographics are summarized in supplementary Table S1 of supporting information and also described elsewhere . Tumour samples were microarray profiled on the Affymetrix U133A&B gene-chips. Microarray analysis was carried out at the Genome institute of Singapore. All microarray data are accessible at NCBI-GEO (http://www.ncbi.nlm.nih.gov/geo/) via series accession number (GSE4922). RNA preparation, microarray hybridization, and data processing were carried out essentially as previously described (Pawitan et al., 2005) . All data were normalized using the global mean method (MAS5), and probe set signal intensities were natural log transformed and scaled by adjusting the mean signal to a target value of log 500. The expression intensity of the POLB probe 234907_x_at, located on the HG-U133b gene chip was utilized for the analysis and to generate artificial neural network (ANN) model. Data were available for 249 patients.
Artificial neural network (ANN) model:
A non-linear, ANN modeling based, data mining approach was utilised for the Uppsala cohort to identify the best gene probes for sample classification. 47,293 probes were screened for each sample. The data mining algorithm comprised a three layer multilayer perception architecture modified with a feed forward backpropagation algorithm and a sigmoidal transfer function, as previously described (Lancashire et al., 2010) . The network momentum and learning rate were respectively set as 0.1 and 0.5.
A parsimonious structure using two hidden nodes and three split Monte Carlo Cross validation were utilised to prevent over fitting. The output node was coded as 0 if a case was low Pol β expression (<the median) and 1 if high Pol β expression (>median). Inputs were ranked in ascending order based on their classification error. The top 100 predictive genes identified were then applied to an ANN based network inference algorithm as described in earlier studies (Lemetre, 2009) . This model predicted a weighted link (direction and magnitude) between each of the top 100 gene probe markers associated with Pol β expression and every other marker in the top 100. The 100 strongest interactions based on the magnitude were then visualised as a map with Cyto-scape (Smoot et al., 2011) .
Ensemble classification and cross-validation analysis:
In a second bioinformatics analysis step in Uppsala cohort, we sought to obtain a robust ranking of genes that are differentially expressed between the mRNA Pol β + cases and the mRNA Pol β -and have high predictive power, by applying an ensemble sample classification method within a leave-one-out crossvalidation scheme. For this purpose, the 249 patient samples were first grouped into 249 different training/test set partitions, using 248 samples for the training sets and the remaining sample as the test set. For each of the 248 training sets differentially expressed genes were selected independently with the "Empirical Bayes moderated t-statistic" (Smyth, 2004) and used to train a machine learning model, which was evaluated based on the left-out sample (a procedure known as "external cross-validation"). To classify the left-out sample, the prediction results of four algorithms (Support Vector Machine, Random Forest, kNN and Prediction Analysis for Microarrays, with all parameters being optimised by using a grid search within a nested cross-validation) (Tibshirani et al., 2002) were combined to a majority-vote ensemble classifier as to compensate for the inevitable inherent biases and variances that exists amongst each of these machine learning algorithms. In order to rank the genes based on the cross-validation results, their frequency of occurrence in the list of significantly differentially expressed genes (p-value < 0.05) across different cross-validation cycles was recorded, and genes received higher scores the more often they had been selected.
All steps of the analysis were conducted using an in-house web-application for microarray analysis, available at www.arraymining.net.
METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) validation cohort
Pol β gene copy number changes as well as pol β mRNA gene expression was performed in METABRIC cohort which refers to a set of 1980 breast cancer samples with a minimum of 5 years of clinical follow up (Curtis et al., 2012) . Patient demographics are summarized in supplementary Table S2 . ER positive and/or lymph-node negative patients did not receive adjuvant chemotherapy. ER negative and/or lymph-node positive patients received adjuvant chemotherapy. For this cohort, mRNA was hybridized to Illumina HT-12 v3 platform (Bead Arrays) and the data were pre-processed and normalized as described previously (Curtis et al., 2012) . Genes copy number was assayed on the Affymetrix SNP 6.0 Samples were classified into the intrinsic subtypes based on the PAM50 gene list. A description of the normalization, segmentation, and statistical analyses was previously described (Curtis et al., 2012) . Real time PCR RT-qPCR was performed on the ABI Prism 7900HT sequence detection system (Applied Biosystems) using SYBR1 Green 
Nottingham Tenovus Primary Breast Carcinoma cohort (NTP-BC)
Pol β protein expression was performed in a consecutive series of 1650 patients with primary invasive breast carcinomas who were diagnosed between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series. All patients were treated uniformly in a single institution and have been investigated in a wide range of biomarker studies Elston and Ellis, 1991; Galea et al., 1992) . Supplemental Table S3 summarizes patient demographics. Supplemental treatment data 1 summarizes various adjuvant treatments received by patients in this cohort.
Early primary ER negative (EP-ER-) BC cohort
We also evaluated Pol β protein expression in an independent series of 281 ER-α negative invasive BCs diagnosed and managed at the Nottingham University Hospitals between 1999 and 2007. All patients were primarily treated with surgery, followed by radiotherapy and anthracycline chemotherapy. The characteristics of this cohort are summarised in supplementary Table S4 .
B. Mechanistic studies
Nottingham (NT) series: Pol β gene copy number changes, mRNA gene expression and protein expression were derived from the 'NT-series' that was a set of 171 stage I and II primary operable invasive BC previously described by our group in several molecular profiling studies (Blenkiron et al., 2007; Chin et al., 2007 Pol β gene copy number changes: Copy number changes at Pol β locus (8p11.21 spanning from 42195973 to 42229321 with size of 33348 bases) were retrieved from oligonucleotide microarrays profiling previously described by our group . Briefly, DNA was extracted using the Promega DNA Wizard kit (Promega, UK) according to manufacturer's instructions. Labelled DNAs were hybridized to a customized 30,000 60-mer oligo probes, for which 27,801 unique map positions were defined [Human Mar. 2006 assembly (hg18) ].
The median interval between mapped elements was 39.4 kb, 75% of intervals were less than 104.2 kb and 95% were less than 402 kb.
Pol β mRNA expression: 128 out of the 171 breast tumours were also profiled on Agilent gene expression arrays and have been previously described . Briefly, total RNA was extracted from a series of frozen breast cancers retrieved from Nottingham Hospitals NHS Trust Tumour Bank between 1986 and 1992. RNA integrity and DNA contamination were analysed using Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA, USA). Total RNA was biotin-labelled using the Illumina TotalPrep RNA Amplification kit (Ambion, Austin, TX, USA) according to manufacturer's instructions.
Biotin-labelled cRNA (1.5 µg) was used for each hybridisation on Sentrix Human-6
BeadChips (Illumina, San Diego, CA, USA) in accordance with the manufacturer's protocol.
Illumina gene expression data containing 47,293 transcripts were analysed and summarised in the Illumina Bead Studio software. Analyses of the probe level data were done using the beadarray Bioconductor package.
Pol β protein expression and other biological biomarkers: The 128 cases which had both a-CGH and mRNA data were then evaluated for Pol β protein expression by immunohistochemistry on tissue microarray (TMAs) as described below. Demographics of this cohort is summarised in supplementary Table S5 . 
Survival data
Survival data including survival time, disease-free survival (DFS), and development of locoregional and distant metastases (DM) were maintained on a prospective basis. DFS was defined as the number of months from diagnosis to the occurrence of recurrence or DM relapse. BC specific survival (BCSS) was defined as the number of months from diagnosis to the occurrence of BC related-death. Survival was censored if the patient was still alive, lost to follow-up, or died from other causes.
The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria were followed throughout this study.
Tissue Microarrays (TMAs) and immunohistochemistry (IHC)
Tumours from NT-BC, NTP-BC and EP-ER-BC cohorts were arrayed in tissue microarrays (TMAs) constructed with 6 replicate 0.6 mm cores from the centre and periphery of the tumors for each patient. The TMAs were immunohistochemically profiled for Pol β and other biological antibodies (Supplementary Table S6 ). Immunohistochemical staining for Pol β was performed using the Thermo Scientific Shandon Sequenza chamber system (REF: 
Evaluation of pol β immunohistochemical staining:
The tumour cores were evaluated by expert pathologists blinded to the clinico-pathological characteristics of patients in two different settings. There was excellent intra and inter-observer agreements (k > 0.8; Cohen's κ and multi-rater κ tests, respectively). In this study, nuclei immunoreactivity was quantitatively evaluated with the Histoscore (H score). The absence (negative) of nuclear staining was given a score of 0 and the presence of nuclear stain was dependent on its intensity as 1, 2 or 3 equivalent to weak, moderate and strong nuclear stain respectively. The percentage staining of each core was defined as 0-100% and the H-score was obtained by multiplying intensity of staining and percentage of staining. H-score in a range of 0 -300 was generated. The median H-score of 100 was taken as the cut-off and low pol β expression was classed as H-score of ≤ 100 and >100 was classed as high for Pol β expression. Not all cores within the TMA were suitable for IHC analysis as some cores were missing or lacked tumour.
Breast cancer cell lines and Western blot analysis: MCF-7, MDA-MB-231 and MDA-MB-436 breast cancer cell lines were purchased from ATCC and grown in RPMI medium supplemented with 10% FBS, 1% penicillin/streptomycin. Western blot analysis performed as described previously (Sultana et al., 2013 
RESULTS
Low Pol β mRNA levels correlate to aggressive breast cancer
In the Uppsala cohort (n=249), low pol β mRNA expression (29%) was associated with lymph node positive disease (p=0.03) (supplementary Table S7 ) and poor survival (p=0.004) ( Figure 1A ). We then proceeded to investigate pol β mRNA expression in a large series of 1950 tumours comprising the METABRIC (Molecular Taxonomy of Breast Cancer
International Consortium) cohort (Table 1) Low pol β mRNA mRNA expression was also found to be associated with previously described molecular phenotypes in breast cancer: PAM50.Her2 (p<0.0001), PAM50.Basal (p<0.0001) molecular phenotypes. However, PAM50.LumA (p<0.0001) and PAM50.LumB (p=0.0097) breast tumours where more likely in tumours that have high levels of pol β mRNA (p<0.0001). Similarly, ER+/Her-2-/high proliferation (p=0.001) and ER+/Her-2-/low proliferation tumours (p<0.0001) were more likely in tumours that have high levels of pol β mRNA whereas low pol β mRNA levels was associated with ER-/Her-2-(p<0.0001) and her-2 positive tumours (p=0.001). Low pol β mRNA expressing tumours had significantly worse breast cancer specific survival compared to tumours with high pol β mRNA levels (p<0.0001) ( Figure 1B) .
The data provides confirmatory evidence that pol β mRNA expression has prognostic significance in breast cancer.
Artificial neural network (ANN), ensemble classification and cross-validation analysis reveals oesotrogen receptor (ESR1) as a novel pol β interaction gene
To investigate pol β interactions in breast cancer, a non-linear, ANN modeling based, data mining approach was utilised to identify the best gene probes for sample classification.
47,293 probes were screened for each sample in 249 breast tumours (Uppsala cohort). ANN, ensemble classification and cross-validation analysis were conducted ( Figure 1C ). The biological functions of pol β interaction genes are summarized in supplementary data 2 and shown in Figure 1C . Oestrogen receptor (ESR1) gene was identified as a key pol β interacting gene in this study. We therefore proceeded to investigate pol β protein expression in breast cancer with a specific focus on ER positive breast cancers.
Low Pol β protein levels correlate to aggressive ER + breast cancers
A total of 1406 tumours were suitable for pol β protein expression analysis. We first investigated specificity of the antibody used in the current study as well as pol β protein expression in a panel of breast cancer cell lines. Compared to MCF-7 and MDA-MB-231 breast cancer cells, MDA-MB-436 had more than 80% reduction in pol β protein expression ( Figure 2A1 ). In human tumours, 540/1406 (38.4%) of the tumours had low pol β protein expression whereas 866/1406 (61.6%) expressed high pol β protein expression ( Figure 2A2 and 2A3) ( .0001) and absence of anti-apoptotic factor (Bcl-2, p=<0.001). Low pol β was significantly associated with poor breast cancer specific survival (BCSS) (p<0.0001) ( Figure   2B1 ) and disease free survival (DFS) (p<0.0001) (Supplementary Figure 1A) . In multivariate cox regression analysis, low pol β protein expression was an independent predictor for BCSS (p=0.022) (Supplementary Table S8 ).
Pol β and ER+ breast cancer:
We then proceeded to perform subgroup analysis in various sub-types of breast cancers. A total of 1009 ER positive tumours were first investigated.
328/1009 (32.5%) of tumours had low pol β protein expression whereas 681/1009 (67.5%) of the tumours had high pol β expression (Table 3) . Low DNA pol β expression was significantly associated with adverse pathological parameters including; high grade (p<0.001), high mitotic index (p<0.001), glandular de-differentiation (p=0.019) and pleomorphisim (p=0.02). Low pol β was associated with low BRCA1 (p<0.0001), low XRCC1 (p<0.001), low FEN1 (p=0.001) and low SMUG1 (p=0.025) protein expression. Low pol β expression was also significantly associated with high proliferation index (MIB1, p=0.005), mutant p53 (p=0.016) and absence of anti-apoptotic factor (Bcl-2, p=0.002). Low pol β was significantly associated with poor BCSS (p<0.0001) (Supplementary Figure 1B) and DFS (p=0.001) (Supplementary Figure 1C) in all ER+ tumours that are high risk (NPI>3.4). Interestingly, in ER+ tumours that received tamoxifen therapy, low pol β remains significantly associated with poor BCSS (p<0.0001) ( Figure 2B2 ) and DFS (Supplementary Figure 1D) . On the other hand, ER+ tumours that did not receive tamoxifen, there was no difference in BCSS between high and low pol β expressing tumours ( Figure 2B3 ) as well as Figure 1E) .
DFS (Supplementary
In Luminal A ER+ breast cancers, low pol β expression remains associated with high mitotic index (p=0.01), HER-2 overexpression (p=0.002), low BRCA1 (p=0.019), XRCC1 (p<0.0001) and FEN1 (p=0.015) (Supplementary Table S9 ). In high risk tumours (NPI>3.4), low pol β was significantly associated with poor BCSS (p=0.001) ( Figure 2C1 ) and DFS (p=0.006) (Supplementary Figure 2A) . In luminal A tumours that received tamoxifen therapy, low pol β remains significantly associated with BCSS (p=0.003) ( Figure 2C2 ) and DFS (p=0.004) (Supplementary Figure 2B) . On the other hand, luminal A tumours that did not receive tamoxifen, there was no difference in BCSS between high and low pol β expressing tumours ( Figure 2C3 ) and DFS (Supplementary Figure 2C) .
In Luminal B ER+ breast cancers, low pol β expression was associated with high grade (p=0.006), high mitotic index (p=0.008), HER-2 overexpression (p=0.002), CK6 (p=0.009), low BRCA1 (p=0.001), XRCC1 (p<0.0001) and FEN1 (p=0.038) (Supplementary Table   S10 ). ). In luminal B tumours that received tamoxifen therapy, low pol β was significantly associated with poor BCSS (p=0.002) ( Figure 2D2 ) but not for DFS (p=0.112) (Supplementary Figure 2E) . In luminal B tumours that did not receive tamoxifen, there was no difference in BCSS between high and low pol β expressing tumours ( Figure 2D3 ) and Figure 2F) .
Taken together the data confirms that low pol β protein expression has clinicopathological, prognostic and predictive significance in ER positive breast cancers.
Pol β and ER-breast cancer:
We then proceeded to investigate pol β protein expression in 363 ER-breast tumours. 192/363 (52.9%) of tumours had low pol β protein expression whereas 171/363 (47.1%) of the tumours had high pol β expression (Supplementary Table S11 ). There were no significant clinicopathological correlations although there were associations with ATM, XRCC1 and DNA-PK expression (Supplementary Table S11 ). We then investigated pol β protein expression in another independent cohort of 347 ER-breast cancers. 229/347 (66%) of tumours had low pol β protein expression whereas 118/347 (34%) of the tumours had high pol β expression (Supplementary Table S12 ). There were no significant clinicopathological correlations although there were some associations with ATM, XRCC1, BRCA1 and Bcl-2 expression. There were no significant associations between pol β protein expression and survival in ER-tumours in both cohorts (Supplementary Figure 3) .
Taken together the data confirms that pol β has no clinical significance in ER negative breast cancers. Whereas in ER positive tumours, pol β deficiency is a poor prognostic as well as a predictive biomarker.
Mechanistic insights
Pol β gene copy number and pol β mRNA levels: Integrated array CGH and mRNA gene expression analysis was conducted in 125 breast tumours (Nottingham cohort) where pol β gene copy number and pol β mRNA expression data were all available. 29%, 8% and 11% of tumours showed gain, amplification and losses of pol β gene locus at chromosome 8p12-p11
respectively. 52% of tumours were neutral for pol β gene copy number. There was a strong correlation between pol β gene copy number changes and pol β mRNA expression in tumours (adjusted p value= 0.00126).
In the METABRIC cohort, integrated array CGH and mRNA gene expression analysis was conducted in 1952 breast tumours. 16.2%, 3.6% and 5.0% showed gain, amplification and losses of pol β gene locus at chromosome 8p12-p11 respectively. 75% of tumours were 20 neutral for pol β gene copy number in the METABRIC cohort. A very strong correlation between gene copy number and mRNA expression was demonstrated in the METABRIC cohort (p=5.6 x 10 -93 ) ( Figure 3A ). Together the data confirms that low pol β mRNA is direct consequence of loss of pol β gene copy number in a proportion of breast tumours.
Pol β mRNA and pol β protein levels: We compared pol β mRNA levels and protein expression in 125 breast tumours (Nottingham cohort). As shown in Figure 3B , there was positive correlation between pol β mRNA and pol β protein expression (r=0.55, p= 2.17x10 -11 ) in tumour. The data suggests that low pol β protein is direct consequence of low pol β mRNA in a proportion of breast tumours.
DISCUSSION
Pol β is a key player in base excision repair and promotes genomic stability. Pol β gene is localised to chromosome 8p12-p11 which is a hot spot for genetic changes in breast cancer (Armes et al., 2004; Kerangueven et al., 1994; Pole et al., 2006; Sigbjornsdottir et al., 2000; Tagawa et al., 2003; Ugolini et al., 1999; Venter et al., 2005) . In the current study we have demonstrated for the first time that pol β gene deletion at chromosome 8 is associated with low pol β mRNA levels as well low pol β protein levels in a proportion of breast cancers.
Low pol β mRNA was significantly linked to aggressive features such as high grade, high mitotic index, pleomorphism, triple negative, PAM50. Her2, PAM50. Basal, PAM50.
Luminal A and PAM50. Luminal B molecular phenotypes. At the protein level, similarly, low pol β expression was associated with aggressive clinical phenotype. Interestingly, low pol β protein also associated with other DNA repair factors such as absent BRCA1, low XRCC1, low FEN1 and low SMUG1 protein expression. The data provides evidence that pol β loss may be associated with genomic instability in breast tumours. In sub-group analysis in ER positive tumour we also observed consistent association with aggressive clinicopathological features. In ER negative tumours, however, no significant associations were evident. Together the data provides evidence for a novel role for pol β in ER positive breast tumours. This hypothesis is further supported by artificial neural network analysis of gene expression in 249 breast tumours, where oestrogen receptor was found to be a top pol β interacting gene. In ER positive tumours we also found that pol β expression predicts resistance to endocrine therapy as evidenced by poor survival in patients whose tumours that had low pol β expression and received tamoxifen therapy. The poor predictive significance was seen in luminal A as well as luminal B tumours implying that pol β is a novel predictive biomarker and is likely related to the role of pol β in cell proliferation. Taken together, our data provides the first compelling evidence that pol β is involved in breast cancer pathogenesis.
Previous studies have shown that about 30% of human solid tumours may harbour pol β variants that have sub-optimal DNA repair capacity, promote genomic instability and confer a mutator phenotype that is associated with aggressive clinical behaviour (Starcevic et al., 2004; Yamtich et al. 2010 ). Whether such pol β variants exist in breast cancer is unknown.
Nevertheless, the data presented in our study suggests that deletions at the chromosome 8p12-p11 locus is a mechanism for pol β deficiency which is associated with an aggressive phenotype in breast cancer. The link between pol β and ER was surprising. However, emerging evidence does suggest a potential association between oestrogen and base excision repair (BER). For example, oestrogen induced oxidative stress may play a key role in oestrogen driven carcinogenesis (Bhat et al., 2003) . Oxidative stress is a major source of oxidative base damage which is a strong stimulus for activation of BER (Amouroux et al., 2010; Cabelof et al., 2002; Unnikrishnan et al., 2011) . In preclinical models, pol β is strongly induced in response to oxidative stress. Accumulation of DNA damage has been demonstrated in cells with reduced pol β levels (Cabelof et al., 2002) . We therefore speculate that in oestrogen/oestrogen receptor driven breast cancers with impaired BER, the consequent genomic instability and accelerated accumulation of mutations may drive an aggressive cancerous phenotype. However, confirmation of such a pol β related mechanism would need detailed pre-clinical studies which is an area of on-going investigation in our laboratory. The association with endocrine therapy resistance and low pol β levels in ER positive tumours implies that pol β is also a promising predictive biomarker. Although the mechanism for resistance is unclear, the high proliferation rate consistently observed in pol β deficient tumours in our study may account for the endocrine resistance seen in patients.
We have recently investigated XRCC1, a key BER factor, in breast cancer. Loss of XRCC1
was associated with high grade, loss of hormone receptors, triple negative, basal like phenotypes and poor survival. In ER+ cohort that received adjuvant endocrine therapy, low XRCC1 remained associated with poor survival (Sultana et al., 2013) . The pol β expression study presented here as well as the XRCC1 data in breast cancer supports the hypothesis that BER pathway may not only operate as a tumour suppressor but BER down-regulation may also result in an aggressive phenotype in breast cancer (Sweasy et al., 2006) . Moreover, in
XRCC1 deficient cells we also demonstrated a novel synthetic lethality application using inhibitors of DNA double strand break repair such as those targeting ATM, DNA-Pk and ATR (Sultana et al., 2013) . Taken together, our data suggests that identification of BER deficiency in breast cancers could be an exciting new approach for a personalized treatment strategy. 
